Eli Lilly And Co vs Clear Secure Inc — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while Clear Secure Inc trades at $43.43 (market cap $4.44B). The key difference: Eli Lilly And Co is far larger — about 234.2× Clear Secure Inc's market cap, and Clear Secure Inc pays the higher dividend (1.33%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Clear Secure Inc for 19 Days on average.
| LLY | YOU | |
|---|---|---|
Market Cap | $1.04T | $4.44B |
Volume | 3,064,878 | 1,477,828 |
Sector | Health | Technology |
52-Week High | $1.28K | $62.36 |
52-Week Low | $799.57 | $29.61 |
Typical Hold Time | 93 Days | 19 Days |
Enterprise Value | $1.09T | $3.59B |
Dividend Yield | 0.59% | 1.33% |
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company's weight-loss drug portfolio continues to drive exceptional performance, with Q2 2026 EPS of $8.38 beating expectations by 31%. Technical indicators show bullish moving averages while fundamentals reveal impressive 83.4% gross margins and 102.44% ROE. Recent clinical trial successes for next-generation obesity treatments position Lilly for continued market leadership.
LLY presents a compelling growth story with dominant positioning in the expanding obesity/diabetes market, though elevated valuations (P/E 39.26) and regulatory risks require monitoring. Analyst consensus remains strongly bullish with $1,350 price target representing 15% upside. The primary investment thesis centers on pipeline execution and market expansion opportunities, balanced against competitive pressures and valuation concerns.
Clear Secure (YOU) trades at $43.08, up 1.17% with strong fundamentals including 27% revenue growth and expanding profitability. The stock shows mixed technical signals with bullish overall momentum but overbought RSI levels. Recent Q2 earnings beat expectations with $0.49 EPS versus $0.40 estimate, while analyst consensus targets $61.40 representing 43% upside potential.
Outlook remains positive with accelerating membership growth and new corporate partnerships driving expansion. Key risks include competitive pressure in identity verification and potential execution challenges. The stock offers growth exposure but requires monitoring of technical overbought conditions and quarterly execution against elevated expectations.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →Clear Secure operates a secure identity platform that uses biometrics—specifically eyes, face, and fingerprints—to automate and expedite identity verification. While its most visible application is the CLEAR Plus airport subscription service, the company functions as a broad-based identity layer for travel, healthcare, and digital services, aiming to replace physical IDs with a secure, biometric link.
Read more on YOU →